Scopio Labs, the developer of the Full-Field Cell Morphology imaging and analysis platform, has unveiled its Complete Blood Morphology (CBM®) analyzer, a first-of-its-kind solution that brings full automation to one of the last remaining manual processes in diagnostics: peripheral blood smear (PBS) review. Designed to scale, streamline, and standardize hematology workflows, CBM® uses Scopio’s proprietary Full-Field imaging technology and AI-driven analysis to autonomously analyze PBS samples, evaluating 10 times more cells than traditional methods. This advancement reduces reliance on human interpretation, minimizes variability, and enhances clinical efficiency.
The launch of CBM® addresses a longstanding bottleneck in the diagnostic process. While Complete Blood Count (CBC) testing has seen decades of automation, PBS review remains labor-intensive and inconsistent, hampered by global workforce shortages, lengthy technologist training cycles, and rising diagnostic demand. These challenges contribute to delayed results and limited scalability—issues that CBM® directly confronts with its autonomous and standardized approach.
To support the commercialization of CBM®, Viola Growth has joined as a new investor, contributing an additional $10 million to Scopio’s Series D funding round, which now totals $52 million. Existing users of Scopio’s CE-marked and FDA-cleared platforms for PBS and bone marrow aspirate analysis are already seeing increased efficiency and are well-positioned to adopt the new CBM® technology.
Scopio CEO and Co-founder Itai Hayut emphasized that the company’s vision is to close the automation gap in hematology entirely by creating a fully integrated process from CBC to final result. He called the CBM® launch a paradigm shift that could reshape hematology workflows and economics. In addition to automating existing tasks, CBM® also holds potential to enable new morphology-based biomarkers and diagnostic panels, opening the door to earlier disease detection and real-time monitoring directly from blood samples.
Click here to read the original news story.